EN DE
STOCK COMPARISON

Cardinal Health vs McKesson: Fair Value & Quality

Both stocks run through our valuation models. Here is how Cardinal Health (CAH) and McKesson (MCK) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Cardinal Health trades at $238 versus a fair value of $142 (-40%), while McKesson trades at $871 versus $819 (-6%).
Cardinal Health
CAH · USD · Health Care
-40%
upside to fair value
overvalued
Price$238
Fair Value$142
Quality68/100
McKesson
MCK · USD · Health Care
-6%
upside to fair value
fairly valued
Price$871
Fair Value$819
Quality65/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Cardinal HealthMcKesson
Valuation
35.2×P/E (TTM)21.0×
0.22×P/S (TTM)0.23×
14.5×EV/EBITDA13.9×
1.45×PEG1.57×
0.9%Dividend yield0.4%
$2.04Dividend per share$3.17
Profitability
1%Net margin1%
1%Operating margin2%
4%Return on assets5%
Growth
11%Revenue growth (YoY)6%
7.1%Avg. growth/yr (3Y)13.4%
7.8%Avg. growth/yr (5Y)11.1%
Balance & size
$54BMarket cap$94B
mixedGrowth qualityhealthy

McKesson leads: 4 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Cardinal Healthof which business quality 61 · market factors 81 McKessonof which business quality 65 · market factors 63
ProfitabilityMargins and returns on capital today
44
49
Quality GrowthAre margins and returns improving?
36
65
CashflowEarnings quality: real cash, not paper profit
44
47
Fin. StrengthBalance sheet, leverage, solvency risk
75
72
InvestmentDisciplined investing over empire-building
84
76
Low VolatilityCalm price path (market factor)
84
83
MomentumPrice trend over the last 3–12 months (market factor)
73
50
52W MomentumDistance to the 52-week high (market factor)
94
63
Net IssuanceBuybacks instead of dilution
100
100

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Cardinal Health

DCF Models$150
Earnings-Based$72.85
Dividend Discount$37.11
Multiples$133
Growth DCF$153
Economic Profit$71.40
Growth Earnings$117

22 of 22 models see the stock below the current price.

McKesson

DCF Models$909
Earnings-Based$444
Dividend Discount$57.26
Multiples$787
Growth DCF$922
Economic Profit$497
Growth Earnings$669

14 of 23 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Cardinal Health
Bear $89.35Fair Value $142Bull $183
$238 = current price (white tick)
McKesson
Bear $605Fair Value $819Bull $1,034
$871 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Cardinal Health · Health Care

Quality score68 · Top 25%
Fair value upside-40% · below median

McKesson · Health Care

Quality score65 · Top 25%
Fair value upside-6% · above median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Cardinal Health trades at $238 versus a fair value of $142 (-40%), while McKesson trades at $871 versus $819 (-6%).

Cardinal Health has the higher quality score (68/100).

See the full analysis →
Cardinal Health · McKesson

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Cardinal Health

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to McKesson

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.